JOHNSON & JOHNSON |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,798 ARS | +0.07% |
|
-2.00% | +6.55% |
| Sales 2024 * | 88.37B 78,120B 7,036B | Sales 2025 * | 90.78B 80,250B 7,228B | Capitalization | 361B 318,934B 28,725B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B 19,482B 1,755B | Net income 2025 * | 23.09B 20,413B 1,839B | EV / Sales 2024 * | 4 x |
| Net cash position 2024 * | 7B 6,185B 557B | Net cash position 2025 * | 21.07B 18,630B 1,678B | EV / Sales 2025 * | 3.74 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
15.9
x | Employees | 131,900 |
| Yield 2024 * |
3.19% | Yield 2025 * |
3.33% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
| 1 day | +0.07% | ||
| 1 week | -2.00% | ||
| Current month | +2.25% | ||
| 1 month | +4.49% | ||
| 3 months | -16.01% | ||
| 6 months | +25.11% | ||
| Current year | +6.55% |
1 week
10 669.50
10 995.00
1 month
10 157.5011 296.00
Current year
9 977.0014 499.00
1 year
4 960.0014 499.00
3 years
1 793.6714 499.00
5 years
361.1714 499.00
10 years
68.1514 499.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 31/12/97 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 04/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 24/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 18/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 21/10/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 10,798 | +0.07% | 6,905 |
| 10/05/24 | 10,790 | -0.33% | 12,830 |
| 09/05/24 | 10,826 | +1.18% | 9,409 |
| 08/05/24 | 10,700 | -1.51% | 8,386 |
| 07/05/24 | 10,863 | -1.42% | 14,084 |
End-of-day quote Buenos Aires S.E., May 12, 2024
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
173.3
USD
Spread / Average Target
+14.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.98% | 684B | |
| +30.34% | 568B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| +7.09% | 166B | |
| -1.22% | 159B |
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
